



Regd. Office: 93, J. P. Road, Andheri (West), Mumbai - 400 058. • Phone: 67 603 603 • Fax: 91-22-6694 3127 Email : info@jenburkt.com • www.jenburkt.com • CIN No. L24230MH1985PLCO36541

Ref: JPL/CS/1339/2016.

Date: 08th January, 2016.

To
The BSE Ltd.,
1st Floor, New Trading Ring,
Rotunda Building, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai - 400 001.

Sub.: Compliance Report on Corporate Governance for the quarter ended on 31st December, 2015.

Ref.: Clause 27(2) of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations 2015.

Stock Code: 524731

Dear Sir / Madam,

Kindly find enclosed a quarterly compliance report on Corporate Governance of the Company in pursuance of Clause 27(2) of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations 2015 for the quarter ended on 31st December, 2015.

You are requested to take on record the same and acknowledge receipt.

Thanking you,

Yours faithfully,

For ÆNBURKT PHARMACEUTICALS LTD.,

ASHISH SHAH
Company Secretary.

Encl.: As stated above.

Jenburkt Pharmaceuticals Limited

Quarter ending

, COHIDOSILI	on of Board of Dire	ectors						
Fitle Mr. / Ms)	Name of the Director	PAN & DIN	Category (Chairperson/E xecutive/Non- Executive/inde pendent/Nomi nee)	Date of Appointment in the current term /cessation	Tenure	No of Directorship in listed entities including this listed entity	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity	No of post of Chairperson in Audit/ Stakeholde Committee held in listed entities including this liste entity
Mr.	Ashish U. Bhuta	AABPB3304P 00226479	Executive/ Chairperson	01/04/2015	-:	1	1	Nil
Mr.	Dilip H. Bhûta	AABPB7336D 03157252	Executive Director	16/07/2013		1	1	Nil
Mr.	Bharat V. Bhate	AARPB0489M 00112361	Non Executive/ Independent Director	30/05/2014	21	1	2	2
Mr.	Rameshchandra J. Vora	AAUPV2122J 00112446	Non Executive/ Independent Director	30/05/2014	17	1	2	0
Mr.	Arun R. Raskapurwala	AACPR2593R 00143983	Non Executive/ Independent Director	30/05/2014	9	1	1	0
Ms.	Anjali S. Dalvi	AALPD9872A 03293810	Non Executive/ Independent Director	24/07/2015	5 Months	1	Nil	Nil
1	Audit Committee			members Bharat V. Bhate		Executive/independent/Nominee Non Executive-Independent Director		
Hom id app	Addit committee				Rameshchandra J. Vora		Non Executive-Independent Director	
						Raskapurwala	Non Executive-Independent Directo	
-						H. Bhuta	Executive Director	
2	Nomination & Remuneration Committee					chandra J. Vora	Non Executive-I	ndependent Directo
					Bhar	at V. Bhate	Committee of the	ndependent Directo
						Raskapurwala	Non Executive-Independent Director	
3	Stakeholders Relationship Committee					at V. Bhate	Non Executive-Independent Director	
	1,				Rameshchandra J. Vora		Non Executive-Independent Directo	
					Achie	sh U. Bhuta	CMD & Exe	ecutive Director.
					Asilis	o. blidta	OIND & EX	- Director



				Ashish U. Bhuta	CMD & Executive Director.		
-				Dilip H. Bhuta	Executive Director & CFO.		
5	Risk Management	Committee(if an	nlicable)	Dilip H. Bhuta	Executive Director & CFO.		
	Till Mariagement	. commerce(ii ap	pricable	Dinp III Briata	Company Secretary		
				Ashish R. Shah			
I Mooting	of Board of Directo						
	of Meeting (if any) in		Date(s) of Meeting (if any) i	n the relevant quarter	Maximum gap between any two		
	quarter				consecutive (in number of days)		
	24/07/2015		27/10/20	96 days			
/ Meeting	g of Committees						
. Audit Co					2		
Date(s) o	of meeting of the	Whether requir	ement of Quorum met (details)	Date(s) of meeting of	Maximum gap between any two		
committe	ee in the relevant			the committee in the	consecutive meetings in number of		
	quarter			previous quarter	days*		
27	7/10/2015	Yes, All four m	nembers attended the meeting	24/07/2015	96 days		
	ion and remunerati			In			
	of meeting of the	Whether requir	rement of Quorum met (details)	Date(s) of meeting of	Maximum gap between any two		
	ee in the relevant	- 1 1		the committee in the	consecutive meetings in number of		
	quarter			previous quarter	days* 96 days		
27	7/10/2015	Yes, All three n	nembers attended the meeting	24/07/2015			
	- Cl-I D II-II	lin Committee					
	e Social Responsibile for meeting of the		rement of Quorum met (details)	Date(s) of meeting of	Maximum gap between any two		
committee in the relevant		whether requirement of Quorum met (uetails)		the committee in the	consecutive meetings in number of		
				previous quarter	days*		
	المتهاجرات ا	Yes, All three n	nembers attended the meeting	24/07/2015			
	ders Relationship Co	1		In	les :		
committee in the relevant quarter		Whether requirement of Quorum met (details)		Date(s) of meeting of	Maximum gap between any two consecutive meetings in number of		
				the committee in the			
		Yes, All three n	nembers attended the meeting	previous quarter 24/07/2015	days* 96 days		
/. Related I	Party Transactions						
		1200		Compliance status (Yes/No/NA)			
	ior approval of audit	t committee obta		NA NA			
Whether pr			orial RDT		NA		
Vhether pr Vhether sh	areholder approval						
Whether pr Whether sh Whether de	areholder approval		omnibus approval have been		NA ·		
Whether pr Whether sh Whether de eviewed by	areholder approval etails of RPT entered y Audit Committee				NA ·		
Whether pr Whether sh Whether de eviewed by /I. Affirmat	areholder approval etails of RPT entered y Audit Committee		omnibus approval have been		NA		
Whether pr Whether sh Whether de eviewed by /I. Affirmat Gr. no.	areholder approval etails of RPT entered y Audit Committee			ulars	NA		
Whether pr Whether sh Whether de eviewed by /I. Affirmat	areholder approval etails of RPT entered y Audit Committee tions	into pursuant to	omnibus approval have been partic				
Whether pr Whether sh Whether de eviewed by /I. Affirmat Gr. no.	areholder approval etails of RPT entered y Audit Committee tions The composition of	into pursuant to	omnibus approval have been partic	igations and disclosure re	equirements) Regulations, 2015.		
Whether sh Whether de reviewed by VI. Affirmat Sr. no.	areholder approval etails of RPT entered y Audit Committee tions The composition of	into pursuant to of Board of Direct of the following o	omnibus approval have been partic	igations and disclosure re	equirements) Regulations, 2015.		
Whether pr Whether sh Whether de reviewed by VI. Affirmat Sr. no.	areholder approval etails of RPT entered y Audit Committee tions The composition of the	into pursuant to of Board of Direct of the following cee	partic partic cors is in terms of SEBI (Listing oblommittees is in terms of SEBI(List	igations and disclosure re	equirements) Regulations, 2015.		
Whether pr Whether sh Whether de eviewed by /I. Affirmat Gr. no.	tareholder approval etails of RPT entered y Audit Committee tions The composition of a. Audit Committee	of Board of Direct of the following cee remuneration cor	partic partic cors is in terms of SEBI (Listing oblommittees is in terms of SEBI(List	igations and disclosure re			

ARM

MUMBAI



٠.

3	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and			
	disclosure requirements) Regulations, 2015.			
4	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing			
	obligations and disclosure requirements) Regulations, 2015.			
5	This report and/or the report submitted in the previous quarter will be placed before the Board of Directors.			

For Jenburkt Pharmaceuticals Ltd.
For JENBURKT PHARMACEUTICALS LTD.

Ashish R. Shah

COMPANY SECRETARY

Company Secretary & Compliance Officer